Idiopathic Hypersomnia (IH) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Idiopathic Hypersomnia (IH) Clinical Trial Report Overview
A total of 42 idiopathic hypersomnia (IH) clinical trials were conducted as of October 2024. The idiopathic hypersomnia (IH) clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials.
| Key Regions | · Asia-Pacific
· North America · Europe |
| Key Countries | · The US
· France · Canada · Japan · The UK |
| Key Sponsor Types | · Company
· Institution · Government |
| Leading Sponsors | · Balance Therapeutics Inc (Inactive)
· Jazz Pharmaceuticals Plc · Takeda Pharmaceutical Co Ltd · Alfresa Holdings Corp · Alkermes Plc |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Idiopathic Hypersomnia (IH) Clinical Trials Segmentation by Regions and Countries
As of October 2024, North America led the idiopathic hypersomnia (IH) clinical trials landscape with more than 45% of the clinical trials conducted there
A few of the key regions considered for idiopathic hypersomnia (IH) clinical trials analysis are North America, Europe, and Asia-Pacific.
In the country-wise analysis, the US had the highest number of idiopathic hypersomnia (IH) clinical trials as of October 2024. Canada had the highest average patient enrollment in idiopathic hypersomnia (IH) clinical trials during the same time.
G7 countries: Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, France had the highest proportion of idiopathic hypersomnia (IH) to central nervous system clinical trials as of October 2024.
E7 countries: Among the E7 (Brazil, Russia, Canada, France, Mexico, Turkey, and Indonesia) countries, Turkey had the highest proportion of idiopathic hypersomnia (IH) to central nervous system clinical trials as of October 2024.
Idiopathic Hypersomnia (IH) Clinical Trials Analysis by Regions, 2024 (%)
Buy the Full Report for More Regional Insights into the Idiopathic Hypersomnia (IH) Clinical Trials
Download a Free Sample Report
Idiopathic Hypersomnia (IH) Clinical Trials Segmentation by Sponsor Types
The key sponsor types for idiopathic hypersomnia (IH) clinical trials are company, institution, and the government. As of October 2024, the company sponsor type conducted more than 71% of idiopathic hypersomnia (IH) clinical trials.
Idiopathic Hypersomnia (IH) Clinical Trials Analysis by Sponsor Types, 2024 (%)
Buy the Full Report for More Sponsor Type Insights into the Idiopathic Hypersomnia (IH) Clinical Trials
Idiopathic Hypersomnia (IH) Clinical Trials - Competitive Landscape
A few of the leading sponsors for idiopathic hypersomnia (IH) clinical trials are:
- Balance Therapeutics Inc (Inactive)
- Jazz Pharmaceuticals Plc
- Takeda Pharmaceutical Co Ltd
- Alfresa Holdings Corp
- Alkermes Plc
In 2024, Balance Therapeutics Inc conducted the highest number of idiopathic hypersomnia (IH) clinical trials.
Idiopathic Hypersomnia (IH) Clinical Trials Analysis by Sponsors, 2024 (%)
Buy the Full Report to Know More about the Leading Sponsors of Idiopathic Hypersomnia (IH) Clinical Trials
Segments Covered in the Report
Idiopathic Hypersomnia (IH) Clinical Trials Regional Outlook (2024)
- North America
- Europe
- Asia-Pacific
Idiopathic Hypersomnia (IH) Clinical Trials Country Outlook (2024)
- The US
- France
- Canada
- Japan
- The UK
Idiopathic Hypersomnia (IH) Clinical Trials Sponsor Type Outlook (2024)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report outlines top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for unaccomplishment.
- The report delves into the enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of global clinical trials Market which helps in identifying key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Jazz Pharmaceuticals Plc
Takeda Pharmaceutical Co Ltd
Alfresa Holdings Corp
Alkermes Plc
CTI Clinical Trial and Consulting Inc
Harmony Biosciences Holdings Inc
NLS Pharmaceutics AG
Quad UK Bidco Ltd
Watch Bidco Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of idiopathic hypersomnia (IH) clinical trials in October 2024?
North America accounted for the highest number of idiopathic hypersomnia (IH) clinical trials as of October 2024.
-
Which country conducted the highest number of idiopathic hypersomnia (IH) clinical trials in October 2024?
The US conducted the highest number of idiopathic hypersomnia (IH) clinical trials as of October 2024.
-
Which sponsor type was the most prominent in the idiopathic hypersomnia (IH) clinical trials in October 2024?
As of October 2024, company sponsor type conducted most of the idiopathic hypersomnia (IH) clinical trials.
-
Which are the leading sponsors of idiopathic hypersomnia (IH) clinical trials?
A few of the leading sponsors of idiopathic hypersomnia (IH) clinical trials are Balance Therapeutics Inc (Inactive), Jazz Pharmaceuticals Plc, Takeda Pharmaceutical Co Ltd, Alfresa Holdings Corp, and Alkermes Plc, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Hypersomnia reports


